Breaking News, Collaborations & Alliances

AGC Biologics & Novelty Nobility Partner for Cell Line Development

The partnership will prepare for Phase I preparations for Novelty Nobility’s bispecific antibody drug candidate.

By: Rachel Klemovitch

Assistant Editor

AGC Biologics entered a multiphase partnership with Novelty Nobility Inc., a clinical-stage biotech company based in South Korea. Novelty Nobility develops innovative antibody drugs, including bispecific antibodies and antibody-drug conjugates (ADCs). The company is currently developing two clinical assets in the United States in immunology and oncology, respectively.  As part of the partnership, AGC Biologics will develop the cell line and create a master cell bank (MCB) for Novelty ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters